Open AccessResistance to bevacizumab in ovarian cancer SKOV3 xenograft due to EphB4 overexpression
Author(s) -
Li Li,
Fangfang Nan,
Qingzhi Guo,
Dongdong Guan,
Chao Zhou
Publication year - 2017
Publication title -
journal of cancer research and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.475
H-Index - 39
eISSN - 0973-1482
pISSN - 1998-4138
DOI - 10.4103/0973-1482.204896
Subject(s) - ovarian cancer , bevacizumab , cancer research , medicine , receptor tyrosine kinase , cancer , pharmacology , combination therapy , drug resistance , receptor , chemotherapy , biology , microbiology and biotechnology
Bevacizumab (BV) is broadly used to treat a number of cancers; however, BV resistance mechanisms and strategies to overcome this resistance are yet to be determined.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom